MiR-145 could inhibit cell invasion and migration by targeting TWIST in Colorectal Cancer [32], TGFBR2/Smad3 axis in bladder cancer [33], phospholipase C epsilon 1 in esophageal squamous cell carcinoma [34], ADAM19 in glioblastoma [35], and TGF-β1 in breast cancer [36]. This evidence concerns the gene TGFBR2 and breast carcinoma.